Drug intelligence / Profile preview

chlorotoxin

Development stage
Phase 1
Lead developer
TransMolecular
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
Intratumoral, Intravenous, Intracavitary
01

Overview

Chlorotoxin is a 36-amino acid disulfide-rich peptide originally isolated from the venom of the deathstalker scorpion (Leiurus quinquestriatus). It acts as a neurotoxin and was first used to characterize chloride channels. Chlorotoxin selectively binds to glioma and other tumor cells, but not normal brain tissue, making it useful for targeting cancer cells in diagnosis, imaging, and therapy. Its mechanism involves blocking small-conductance chloride channels and binding preferentially to matrix metalloproteinase-2 (MMP-2), which is upregulated in gliomas and related cancers. This interaction inhibits MMP2 activity, reducing tumor cell migration by preventing cell shrinkage and detachment from the extracellular matrix. Chlorotoxin has been developed into synthetic analogs such as Iodine-131-labeled versions for targeted radiotherapy of brain tumors like glioma. It is under investigation for use against several solid tumors including melanoma, small cell lung carcinoma, neuroblastoma, and medulloblastoma[1][2][4][5][6][7][8]. Chlorotoxin’s ability to cross or deeply penetrate into brain tumors makes it promising for drug delivery applications in neuro-oncology. The exact primary receptor remains debated; besides MMP2 and chloride channels, annexin A2 has also been proposed as a possible target[1][6][8]. No major toxicities or immunogenic responses have been reported in human studies so far.

Other names
chlorotoxin
02

Targets

CLCN3 (Chloride channel protein 3)NRP1 (Neuropilin-1)MMP2 (Matrix metalloproteinase-2)

Beyond the preview

Go deeper on chlorotoxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlorotoxin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call